We can’t show the full text here under this license. Use the link below to read it at the source.
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
New treatments for non-alcoholic fatty liver disease focusing on gut bacteria
AI simplified
Abstract
Non-alcoholic fatty liver disease (NAFLD) is increasingly prevalent, with no current drugs available for treatment.
- Weight loss and a healthy diet combined with exercise are the primary therapeutic options for NAFLD.
- Dysregulated gut microbiota is linked to the development of NAFLD, making it a potential therapeutic target.
- Interventions such as antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites may modulate gut microbiota.
- Recent advances in gut microbiota-targeted therapies for NAFLD have been observed in both clinical and experimental studies.
- Novel therapeutic targets and strategies for treating NAFLD are being critically evaluated.
AI simplified